Life Science Analytics Market - Global Forecast To 2030
商品番号 : SMB-28324
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年5月 |
| ページ数 | 405 |
| 図表数 | 516 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
本レポートは、ライフサイエンス分析市場を分析し、タイプ、コンポーネント、用途、エンドユーザー、地域に基づいて、様々なセグメントの市場規模と将来の成長ポテンシャルを推定することを目的としています。また、市場成長に影響を与える要因（成長の原動力、機会、課題など）についても考察しています。本レポートは、ステークホルダーにとっての機会と課題を評価し、マイクロマーケットの成長傾向、見通し、そしてライフサイエンス分析市場全体への貢献度の観点から考察しています。さらに、5つの主要地域における市場セグメントの収益予測も提供しています。さらに、主要プレーヤーの競合分析に加え、各社の企業概要、製品ラインナップ、最近の動向、主要な市場戦略についても解説しています。
Report Overview
The global life science analytics market is projected to reach USD 68.81 billion by 2030 from USD 40.03 billion in 2025, at a CAGR of 11.4% during the forecast period. The market is anticipated to grow due to the complexity and diversity of big data in the life sciences sector. There is an increasing demand for advanced analytical solutions for various applications across the industry, including research and development, commercialization (such as market access, pricing, and sales and marketing), and safety. Additionally, the market has grown because of the need for better data standardization in the life sciences and healthcare industries. However, challenges to market growth include inadequate IT infrastructure and a reluctance to adopt analytics solutions in emerging economies.
世界のライフサイエンス分析市場は、2025年の400億3,000万米ドルから2030年には688億1,000万米ドルに達し、予測期間中に年平均成長率（CAGR）11.4%で成長すると予測されています。ライフサイエンス分野におけるビッグデータの複雑性と多様性により、市場の成長が見込まれています。研究開発、商品化（市場アクセス、価格設定、販売・マーケティングなど）、安全性など、業界全体で様々な用途において、高度な分析ソリューションに対する需要が高まっています。さらに、ライフサイエンスおよびヘルスケア業界におけるデータ標準化の強化も市場の成長を支えています。しかしながら、市場の成長を阻む課題として、ITインフラの不足や新興国における分析ソリューション導入への消極的な姿勢などが挙げられます。
“The software-as-a-service (SaaS) subsegment is expected to register the highest growth during the forecast period.”
The life science analytics software segment is further segmented into on-premise, cloud-based, and software-as-a-service. The software-as-a-service (SaaS) segment is expected to register the highest growth during the forecast period. The growth of the SaaS segment can be attributed to the ample number of advantages offered by this model, such as the seamless integration of data from various cloud silos, unlimited user access from remote locations, low maintenance costs, high security, privacy, easy accessibility, no upfront capital investment for hardware, and extreme capacity flexibility and optimized resource utilization. Moreover, several applications offered by the SaaS model, spanning areas such as accounting, performance monitoring, and communication through webmail and instant messengers, further contribute to the segment’s growth.
“Pharmaceutical & biotechnology companies are expected to dominate the life science analytics market during the forecast period.”
Pharmaceutical & biotechnology companies, medical device companies, research institutes, and outsourced life science organizations make up the end-user segments of the life science analytics market. In 2024, pharmaceutical & biotechnology companies accounted for a significant share of the life science analytics market, by end user. This segment is also expected to register the highest growth during the forecast period. The prominent position & high growth of this segment are due to the increasing R&D expenditure of pharma & biotech companies, the increasing use of analytics for research & development processes, the growing importance of analytics in pharmacovigilance, the need to accelerate drug discovery and optimize clinical trials, and the need to enhance regulatory compliance through data-driven insights. Moreover, the push for personalized medicine and precision therapeutics and the integration of Al and machine learning further strengthen the value of analytics in the pharma & biotech industry.
“Asia Pacific is expected to register the highest market growth during the forecast period.”
The life science analytics market is bifurcated into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is expected to register the highest growth during the forecast period. The high growth of this region can be attributed to the presence of a large and growing patient population in the region, the increasing need for innovative therapies, the emergence of big data in healthcare, increasing spending on HCIT infrastructure, and the shifting focus of various market players on emerging countries in the region. Government initiatives to promote the adoption of digital & technologically enabled solutions across the life science industry and the significant focus on integrating sophisticated technologies across workflows also contribute to market growth.
The breakdown of primary participants is as mentioned below:
- By Company Type: Tier 1 (32%), Tier 2 (44%), and Tier 3 (24%)
- By Designation: Directors (30%), Managers (34%), and Others (36%)
- By Region: North America (40%), Europe (28%), Asia Pacific (20%), Latin America (7%), and the Middle East & Africa (5%)
List of Companies Profiled in the Report
o Oracle (US)
o Merative (formerly IBM) (US)
o SAS Institute (US)
o Accenture (Ireland)
o IQVIA (US)
o Cognizant (US)
o Wipro (India)
o Veradigm (US)
o Optum (US)
o Microsoft (US)
o MaxisIT (US)
o ExlService Holdings (US)
o Inovalon (US)
o CitiusTech (US)
o Saama (US)
o Axtria (US)
o Clarivate (UK)
o ThoughtSphere (US)
o ThoughtSpot (US)
o Salesforce (US)
o Google LLC (US)
o Amazon Web Services, Inc. (US)
o Veeva Systems (US)
o Elsevier (Netherlands)
o Komodo Health, Inc. (US)
Research Coverage:
The report provides an analysis of the life science analytics market and aims to estimate the market size and future growth potential of various segments based on type, component, application, end user, and region. It also examines factors affecting market growth, including drivers, opportunities, and challenges. The report evaluates the opportunities and challenges for stakeholders and explores micromarkets in terms of their growth trends, prospects, and contributions to the overall life science analytics market. Additionally, the report forecasts the revenue of market segments across five major regions. It includes a competitive analysis of the key players in the market, accompanied by their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.
This report provides insights on:
- Analysis of key drivers (rising pressure to curb healthcare spending, need for improved data standardization, technological advancements in analytical solutions, heterogeneity and complexity of big data in life sciences, growing adoption of analytical solutions in clinical trials, and increasing R&D expenditure in pharmaceutical & biotechnology companies), restraints (high implementation costs of advanced analytical solutions and data privacy concerns), opportunities (growing focus on value-based care, use of analytics in precision & personalized medicine, big data analytics for R&D productivity, and growing adoption of cloud-based analytics), and challenges (issues associated with data integration, shortage of skilled personnel, and reluctance to adopt life science analytics solutions in emerging countries) are factors contributing the growth of the life science analytics market.
- Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the life science analytics market.
- Market Development: Comprehensive information on the lucrative emerging markets, type of solution, component, deployment model, industry, and region.
- Market Diversification: Exhaustive information about the software portfolios, growing geographies, recent developments, and investments in the life science analytics market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global life science analytics market such as Oracle (US), Merative (formerly IBM) (US), SAS Institute (US), Accenture (Ireland), IQVIA (US), Cognizant (US), Wipro (India), Veradigm (US), and Optum (US)
Table of Contents
1 INTRODUCTION 37
1.1 STUDY OBJECTIVES 37
1.2 MARKET DEFINITION 37
1.3 STUDY SCOPE 38
1.3.1 MARKETS COVERED AND REGIONAL SCOPE 38
1.3.2 INCLUSIONS & EXCLUSIONS 39
1.3.3 YEARS CONSIDERED 39
1.3.4 CURRENCY CONSIDERED 40
1.4 STAKEHOLDERS 40
1.5 SUMMARY OF CHANGES 41
2 RESEARCH METHODOLOGY 42
2.1 RESEARCH DATA 42
2.1.1 SECONDARY DATA 42
2.1.1.1 Key data from secondary sources 43
2.1.2 PRIMARY DATA 44
2.1.2.1 Key industry insights 45
2.2 MARKET SIZE ESTIMATION 46
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 51
2.4 MARKET SHARE ESTIMATION 52
2.5 RESEARCH ASSUMPTIONS 52
2.6 RESEARCH LIMITATIONS 52
2.6.1 METHODOLOGY-RELATED LIMITATIONS 52
2.6.2 SCOPE-RELATED LIMITATIONS 52
2.7 RISK ANALYSIS 53
3 EXECUTIVE SUMMARY 54
4 PREMIUM INSIGHTS 58
4.1 LIFE SCIENCE ANALYTICS MARKET OVERVIEW 58
4.2 LIFE SCIENCE ANALYTICS MARKET, BY REGION 59
4.3 NORTH AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY END USER AND COUNTRY 60
4.4 LIFE SCIENCE ANALYTICS MARKET: GEOGRAPHIC SNAPSHOT 61
4.5 LIFE SCIENCE ANALYTICS MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES 61
5 MARKET OVERVIEW 62
5.1 INTRODUCTION 62
5.2 MARKET DYNAMICS 62
5.2.1 DRIVERS 63
5.2.1.1 Rising pressure to curb healthcare spending 63
5.2.1.2 Need for improved data standardization 64
5.2.1.3 Technological advancements in analytical solutions 65
5.2.1.4 Heterogeneity and complexity of big data in life sciences 66
5.2.1.5 Growing adoption of analytical solutions in clinical trials 67
5.2.1.6 Increasing R&D expenditure in pharmaceutical & biotechnology companies 68
5.2.2 RESTRAINTS 69
5.2.2.1 High implementation costs of advanced analytical solutions 69
5.2.2.2 Data privacy concerns 69
5.2.3 OPPORTUNITIES 71
5.2.3.1 Growing focus on value-based care 71
5.2.3.2 Use of analytics in precision & personalized medicine 71
5.2.3.3 Big data analytics for R&D productivity 72
5.2.3.4 Growing adoption of cloud-based analytics 73
5.2.4 CHALLENGES 73
5.2.4.1 Issues associated with data integration 73
5.2.4.2 Shortage of skilled personnel 74
5.2.4.3 Reluctance to adopt life science analytics solutions in emerging countries 74
5.3 INDUSTRY TRENDS 75
5.3.1 GROWING ADOPTION OF ANALYTICS IN COMMERCIAL OPERATIONS 75
5.3.2 LEVERAGING DATA & ANALYTICS TO ACCELERATE
DRUG DISCOVERY & DEVELOPMENT 76
5.3.3 FOCUS ON REAL-TIME DATA ANALYTICS 76
5.4 TECHNOLOGY ANALYSIS 77
5.4.1 KEY TECHNOLOGIES 77
5.4.1.1 Artificial intelligence and machine learning 77
5.4.1.2 Big data analytics 77
5.4.1.3 Quantum computing 78
5.4.2 COMPLEMENTARY TECHNOLOGIES 78
5.4.2.1 Bioinformatics tools 78
5.4.2.2 Internet of Things 78
5.4.3 ADJACENT TECHNOLOGIES 79
5.4.3.1 Blockchain 79
5.5 ECOSYSTEM ANALYSIS 79
5.6 VALUE CHAIN ANALYSIS 82
5.7 PORTER’S FIVE FORCES ANALYSIS 83
5.7.1 THREAT OF NEW ENTRANTS 84
5.7.2 THREAT OF SUBSTITUTES 84
5.7.3 BARGAINING POWER OF SUPPLIERS 84
5.7.4 BARGAINING POWER OF BUYERS 85
5.7.5 INTENSITY OF COMPETITIVE RIVALRY 85
5.8 KEY STAKEHOLDERS AND BUYING CRITERIA 85
5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS 85
5.8.2 BUYING CRITERIA 87
5.9 CASE STUDY ANALYSIS 88
5.9.1 NOVARTIS USES MULTI-CLOUD DATA ANALYTICS PLATFORM TO OPTIMIZE OPERATIONS AND ACCELERATE INNOVATION 88
5.9.2 SAS VISUAL ANALYTICS HELPS MAXIMIZE PROFITABILITY THROUGH PRESCRIPTIVE ANALYTICS & DATA VISUALIZATION 89
5.9.3 STREAMLINING REGULATORY MONITORING AND IMPACT ASSESSMENTS: GEDEON RICHTER’S PARTNERSHIP WITH CLARIVATE 89
5.10 REGULATORY LANDSCAPE 90
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90
5.10.2 NORTH AMERICA 93
5.10.3 EUROPE 93
5.10.4 ASIA PACIFIC 94
5.10.5 MIDDLE EAST & AFRICA 94
5.10.6 LATIN AMERICA 95
5.11 PRICING ANALYSIS 95
5.11.1 AVERAGE SELLING PRICE OF KEY PLAYERS, BY APPLICATION 96
5.11.2 AVERAGE SELLING PRICE, BY REGION 96
5.12 KEY CONFERENCES AND EVENTS, 2025–2026 97
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 98
5.14 PATENT ANALYSIS 98
5.14.1 PATENT PUBLICATION TRENDS 98
5.14.2 JURISDICTION ANALYSIS: TOP APPLICANT 99
5.14.3 MAJOR PATENTS 100
5.15 END USER ANALYSIS 102
5.15.1 UNMET NEEDS 102
5.15.2 END-USER EXPECTATIONS 103
5.16 LIFE SCIENCE ANALYTICS BUSINESS MODELS 104
5.16.1 SUBSCRIPTION-BASED MODEL 104
5.16.2 SAAS MODEL 105
5.16.3 PAY-PER-USE/USAGE-BASED MODEL 105
5.16.4 ENTERPRISE LICENSING 105
5.16.5 FREEMIUM MODEL 105
5.16.6 ENTERPRISE LICENSING 105
5.16.7 CONCURRENT LICENSING 105
5.16.8 CONSULTING SERVICES MODEL 105
5.16.9 PARTNERSHIP/REVENUE-SHARING MODEL 105
5.16.10 HYBRID MODELS 106
5.17 INVESTMENT & FUNDING SCENARIO 106
5.18 IMPACT OF AI/GENERATIVE AI ON LIFE SCIENCE ANALYTICS MARKET 108
5.18.1 TOP USE CASES & MARKET POTENTIAL 108
5.18.1.1 Key use cases 110
5.18.2 CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION 111
5.18.2.1 Case study 1: Knowledge mining for a global biopharmaceutical company 111
5.18.2.2 Healthcare analytics market 112
5.18.3 USER READINESS AND IMPACT ASSESSMENT 113
5.18.3.1 User readiness 113
5.18.3.1.1 Pharmaceutical & biotechnology companies 113
5.18.3.1.2 Medical device companies 113
5.18.3.1.3 Research centers 113
5.18.3.1.4 Outsourced life science organizations 113
5.18.3.2 Impact assessment 114
5.18.3.2.1 User A: Pharmaceutical & biotechnology companies 114
5.18.3.2.1.1 Implementation 114
5.18.3.2.1.2 Impact 114
5.18.3.2.2 User B: Medical device companies 115
5.18.3.2.2.1 Implementation 115
5.18.3.2.2.2 Impact 115
5.18.3.2.3 User C: Research institutes 116
5.18.3.2.3.1 Implementation 116
5.18.3.2.3.2 Impact 116
5.18.3.2.4 User D: Outsourced life science organizations 117
5.18.3.2.4.1 Implementation 117
5.18.3.2.4.2 Impact 117
6 IMPACT OF 2025 US TARIFF—OVERVIEW 118
6.1 INTRODUCTION 118
6.2 KEY TARIFF RATES 118
6.3 PRICE IMPACT ANALYSIS 119
6.4 IMPACT ON COUNTRY/REGION 120
6.4.1 US 120
6.4.2 EUROPE 121
6.4.3 ASIA PACIFIC 121
6.5 IMPACT ON END-USE INDUSTRIES 122
7 LIFE SCIENCE ANALYTICS MARKET, BY TYPE 123
7.1 INTRODUCTION 124
7.2 DESCRIPTIVE ANALYTICS 124
7.2.1 ADVANCED VISUAL DATA EXPLORATION AND SUPPORT FOR INNOVATION TO DRIVE DEMAND 124
7.3 PREDICTIVE ANALYTICS 126
7.3.1 SIMULATION DEVELOPMENT FOR PREDICTING FUTURE TRENDS TO PROPEL MARKET GROWTH 126
7.4 PRESCRIPTIVE ANALYTICS 127
7.4.1 REAL-TIME ANALYSIS FOR IMPROVED DECISION-MAKING TO SUPPORT MARKET GROWTH 127
8 LIFE SCIENCE ANALYTICS MARKET, BY COMPONENT 129
8.1 INTRODUCTION 130
8.2 SERVICES 130
8.2.1 MANAGED SERVICES 132
8.2.1.1 Analytical services 133
8.2.1.1.1 Focus on expediting approvals and product launches to drive growth 133
8.2.1.2 Consulting services 134
8.2.1.2.1 Support for R&D, process development, and other workflow processes to drive market 134
8.2.2 PROFESSIONAL SERVICES 136
8.2.2.1 Training & implementation services 137
8.2.2.1.1 Stringent regulations, increasing competition, and need for skill development to propel demand 137
8.2.2.2 Maintenance & support services 138
8.2.2.2.1 Rising complexity of analytical technologies and expanding research needs to support market growth 138
8.2.2.3 Other professional services 139
8.3 SOFTWARE 140
8.3.1 ON-PREMISES 142
8.3.1.1 Provision of multivendor architecture and security benefits to drive market 142
8.3.2 CLOUD-BASED 143
8.3.2.1 Real-time analysis and elimination of purchasing costs for software & hardware to drive adoption 143
8.3.3 SAAS-BASED 145
8.3.3.1 Increasing adoption of digital solutions and advantages of cloud-based models to drive growth 145
9 LIFE SCIENCE ANALYTICS MARKET, BY APPLICATION 147
9.1 INTRODUCTION 148
9.2 RESEARCH & DEVELOPMENT 148
9.2.1 CLINICAL TRIALS 151
9.2.1.1 Laboratory services 153
9.2.1.1.1 Better accuracy, efficiency, and data interpretation to support demand for lab services 153
9.2.1.2 Patient recruitment services 154
9.2.1.2.1 Need for better candidate identification and enrollment forecasting to propel market growth 154
9.2.1.3 Site identification services 155
9.2.1.3.1 Benefits in locating ideal trial sites and interpreting data to support adoption 155
9.2.1.4 Other clinical trial services 156
9.2.1.5 Life science analytics market for clinical trials, by phase 157
9.2.1.6 PHASE I 158
9.2.1.6.1 Strong pipeline of pharmaceutical companies to propel market growth 158
9.2.1.7 PHASE II 159
9.2.1.7.1 Extended duration of phase II studies to create growth opportunities for CROs 159
9.2.1.8 PHASE III 160
9.2.1.8.1 Rising trial expenditure to drive demand for cost-effective clinical research services 160
9.2.2 PRECLINICAL & DRUG DISCOVERY 161
9.2.2.1 Ability to assist researchers in process innovation and decision support to drive adoption 161
9.3 COMMERCIAL ANALYTICS 163
9.3.1 SALES & MARKETING SUPPORT 165
9.3.1.1 Rising analysis of digital marketing effectiveness to drive adoption 165
9.3.2 MARKET ACCESS 166
9.3.2.1 Focus on strategic pricing, reimbursement, and policy changes to support market growth 166
9.3.3 RWE & VALUE EVIDENCE 167
9.3.3.1 Increased data integration, partnerships, and technological to propel use of RWE 167
9.3.4 ENGAGEMENT SERVICES 169
9.3.4.1 Need for better patient engagement, digital advancements, and AI integration to propel market 169
9.4 REGULATORY COMPLIANCE 170
9.4.1 STRINGENT REQUIREMENTS FOR COMPLIANCE ADHERENCE TO DRIVE ADOPTION 170
9.5 MANUFACTURING & SUPPLY CHAIN OPTIMIZATION 171
9.5.1 RISING NEED FOR REDUCING LOGISTICS COSTS TO SUPPORT MARKET GROWTH 171
9.6 SAFETY 173
9.6.1 PHARMACOVIGILANCE 174
9.6.1.1 Monitoring of drug trials and medication programs to fuel market uptake 174
9.6.2 MEDICAL DEVICE SAFETY 175
9.6.2.1 Stringent safety standards, rigorous risk assessments, and robust quality control to drive demand 175
9.6.3 DIAGNOSTIC VIGILANCE 176
9.6.3.1 Continuous monitoring, integration of diverse data sources, and ongoing education to enhance accuracy and thoroughness 176
10 LIFE SCIENCE ANALYTICS MARKET, BY END USER 178
10.1 INTRODUCTION 179
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 179
10.2.1 RISING NEED FOR INNOVATIVE THERAPIES TO DRIVE ANALYTICS USAGE IN PRODUCT DEVELOPMENT 179
10.3 MEDICAL DEVICE COMPANIES 181
10.3.1 ADOPTION OF DATA ANALYTICS FOR DEVICE COMMERCIALIZATION
TO DRIVE MARKET 181
10.4 RESEARCH CENTERS 182
10.4.1 NEED FOR ANALYZING LARGE VOLUMES OF DATA TO
SUPPORT MARKET GROWTH 182
10.5 OUTSOURCED LIFE SCIENCE ORGANIZATIONS 183
10.5.1 RISING R&D OUTSOURCING BY LIFE SCIENCE COMPANIES TO DRIVE MARKET 183
11 LIFE SCIENCE ANALYTICS MARKET, BY REGION 184
11.1 INTRODUCTION 185
11.2 NORTH AMERICA 185
11.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 186
11.2.2 US 192
11.2.2.1 Established economy and increasing R&D expenditure to drive adoption of analytical solutions 192
11.2.3 CANADA 197
11.2.3.1 Rising need for data standardization in life sciences to fuel uptake 197
11.3 EUROPE 202
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 202
11.3.2 GERMANY 208
11.3.2.1 Growing R&D investments by pharmaceutical & biotechnology companies to drive market 208
11.3.3 FRANCE 213
11.3.3.1 Growing government support for adoption of AI & big data analytics to drive market 213
11.3.4 UK 218
11.3.4.1 Rising clinical trial activity to drive uptake of life science analytics solutions 218
11.3.5 ITALY 222
11.3.5.1 Growing number of drug approvals to drive uptake of analytics solutions 222
11.3.6 SPAIN 227
11.3.6.1 Surging government investments focusing on personalized medicine to drive growth 227
11.3.7 REST OF EUROPE 232
11.4 ASIA PACIFIC 236
11.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 237
11.4.2 JAPAN 243
11.4.2.1 Growing government support for clinical R&D activities to drive adoption 243
11.4.3 CHINA 248
11.4.3.1 Growth in life science industry to support adoption of solutions 248
11.4.4 INDIA 253
11.4.4.1 Rising R&D expenditure and drug development to support market growth 253
11.4.5 REST OF ASIA PACIFIC 258
11.5 LATIN AMERICA 263
11.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK 263
11.5.2 BRAZIL 268
11.5.2.1 Brazil to dominate life science analytics market in Latin America 268
11.5.3 MEXICO 273
11.5.3.1 Growing prominence of startups and rising R&D activity to propel market 273
11.5.4 REST OF LATIN AMERICA 278
11.6 MIDDLE EAST & AFRICA 283
11.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 283
11.6.2 GCC COUNTRIES 289
11.6.2.1 Rising investments, advancements, and developing healthcare infrastructure to drive market 289
11.6.3 REST OF MIDDLE EAST & AFRICA 294
12 COMPETITIVE LANDSCAPE 299
12.1 OVERVIEW 299
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 299
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN LIFE SCIENCE ANALYTICS MARKET 300
12.3 REVENUE ANALYSIS 303
12.4 MARKET SHARE ANALYSIS 303
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 305
12.5.1 STARS 305
12.5.2 EMERGING LEADERS 305
12.5.3 PERVASIVE PLAYERS 305
12.5.4 PARTICIPANTS 306
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 307
12.5.5.1 Company footprint 307
12.5.5.2 Region footprint 308
12.5.5.3 Type footprint 309
12.5.5.4 Application footprint 310
12.5.5.5 Component footprint 311
12.5.5.6 End user footprint 312
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 313
12.6.1 PROGRESSIVE COMPANIES 313
12.6.2 RESPONSIVE COMPANIES 313
12.6.3 DYNAMIC COMPANIES 313
12.6.4 STARTING BLOCKS 313
12.6.5 COMPETITIVE BENCHMARKING 315
12.7 BRAND/SOFTWARE COMPARATIVE ANALYSIS 317
12.8 COMPANY VALUATION AND FINANCIAL METRICS 318
12.9 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF LIFE SCIENCE ANALYTICAL VENDORS 318
12.10 COMPETITIVE SCENARIO 319
12.10.1 PRODUCT LAUNCHES & ENHANCEMENTS 319
12.10.2 DEALS 320
13 COMPANY PROFILES 323
13.1 KEY PLAYERS 323
13.1.1 ORACLE 323
13.1.1.1 Business overview 323
13.1.1.2 Products & services offered 324
13.1.1.3 Recent developments 326
13.1.1.3.1 Product launches & enhancements 326
13.1.1.3.2 Deals 326
13.1.1.4 MnM view 327
13.1.1.4.1 Key strengths 327
13.1.1.4.2 Strategic choices 328
13.1.1.4.3 Weaknesses & competitive threats 328
13.1.2 MERATIVE 329
13.1.2.1 Business overview 329
13.1.2.2 Products & services offered 329
13.1.2.3 Recent developments 330
13.1.2.3.1 Deals 330
13.1.2.3.2 Other developments 330
13.1.2.4 MnM view 330
13.1.2.4.1 Right to win 330
13.1.2.4.2 Strategic choices 330
13.1.2.4.3 Weaknesses & competitive threats 331
13.1.3 SAS INSTITUTE INC. 332
13.1.3.1 Business overview 332
13.1.3.2 Products & services offered 333
13.1.3.3 Recent developments 333
13.1.3.3.1 Product launches & enhancements 333
13.1.3.3.2 Deals 334
13.1.3.4 MnM view 335
13.1.3.4.1 Right to win 335
13.1.3.4.2 Strategic choices 335
13.1.3.4.3 Weaknesses & competitive threats 335
13.1.4 ACCENTURE 336
13.1.4.1 Business overview 336
13.1.4.2 Products offered 338
13.1.4.3 Recent developments 338
13.1.4.3.1 Product launches & enhancements 338
13.1.4.3.2 Deals 339
13.1.4.3.3 Other developments 339
13.1.4.4 MnM view 340
13.1.4.4.1 Right to win 340
13.1.4.4.2 Strategic choices 340
13.1.4.4.3 Weaknesses & competitive threats 340
13.1.5 IQVIA INC. 341
13.1.5.1 Business overview 341
13.1.5.2 Products & services offered 342
13.1.5.3 Recent developments 344
13.1.5.3.1 Product launches & enhancements 344
13.1.5.3.2 Deals 345
13.1.5.3.3 Other developments 345
13.1.5.4 MnM view 346
13.1.5.4.1 Right to win 346
13.1.5.4.2 Strategic choices 346
13.1.5.4.3 Weaknesses & competitive threats 346
13.1.6 COGNIZANT 347
13.1.6.1 Business overview 347
13.1.6.2 Products & services offered 348
13.1.6.3 Recent developments 350
13.1.6.3.1 Product launches & enhancements 350
13.1.6.3.2 Deals 350
13.1.7 WIPRO 351
13.1.7.1 Business overview 351
13.1.7.2 Products & services offered 353
13.1.7.3 Recent developments 354
13.1.7.3.1 Deals 354
13.1.8 VERADIGM LLC 355
13.1.8.1 Business overview 355
13.1.8.2 Products & services offered 356
13.1.8.3 Recent developments 357
13.1.8.3.1 Product launches & enhancements 357
13.1.8.4 Recent developments 357
13.1.8.4.1 Deals 357
13.1.9 OPTUM, INC. 358
13.1.9.1 Business overview 358
13.1.9.2 Products & services offered 359
13.1.10 MICROSOFT 360
13.1.10.1 Business overview 360
13.1.10.2 Products & services offered 361
13.1.10.3 Recent developments 362
13.1.10.3.1 Product launches & enhancements 362
13.1.10.3.2 Deals 362
13.1.11 MAXISIT 363
13.1.11.1 Business overview 363
13.1.11.2 Products & services offered 363
13.1.11.3 Recent developments 364
13.1.11.3.1 Product launches & enhancements 364
13.1.12 EXLSERVICE HOLDINGS, INC. 365
13.1.12.1 Business overview 365
13.1.12.2 Products & services offered 366
13.1.12.3 Recent developments 367
13.1.12.3.1 Product launches & enhancements 367
13.1.12.3.2 Deals 367
13.1.13 INOVALON 368
13.1.13.1 Business overview 368
13.1.13.2 Products & services offered 369
13.1.13.3 Recent developments 370
13.1.13.3.1 Product launches & enhancements 370
13.1.13.3.2 Deals 370
13.1.14 CITIUSTECH INC. 371
13.1.14.1 Business overview 371
13.1.14.2 Products & services offered 371
13.1.14.3 Recent developments 372
13.1.14.3.1 Product launches & enhancements 372
13.1.14.3.2 Deals 373
13.1.14.3.3 Expansions 373
13.1.15 SAAMA 374
13.1.15.1 Business overview 374
13.1.15.2 Products & services offered 374
13.1.15.3 Recent developments 375
13.1.15.3.1 Product launches & enhancements 375
13.1.15.4 Recent developments 376
13.1.15.4.1 Deals 376
13.1.15.4.2 Other developments 376
13.1.16 AXTRIA 377
13.1.16.1 Business overview 377
13.1.16.2 Products & services offered 377
13.1.16.3 Recent developments 378
13.1.16.3.1 Product launches & enhancements 378
13.1.16.3.2 Deals 378
13.1.16.3.3 Expansions 378
13.1.17 CLARIVATE 379
13.1.17.1 Business overview 379
13.1.17.2 Products & services offered 381
13.1.17.3 Recent developments 382
13.1.17.3.1 Product launches & enhancements 382
13.1.17.3.2 Deals 383
13.1.18 THOUGHTSPHERE 384
13.1.18.1 Business overview 384
13.1.18.2 Products & services offered 385
13.1.19 THOUGHTSPOT INC. 386
13.1.19.1 Business overview 386
13.1.19.2 Products & services offered 386
13.1.19.3 Recent developments 387
13.1.19.3.1 Product launches & enhancements 387
13.1.19.3.2 Deals 387
13.1.20 SALESFORCE, INC. 388
13.1.20.1 Business overview 388
13.1.20.2 Products & services offered 389
13.1.20.3 Recent developments 390
13.1.20.3.1 Product launches & enhancements 390
13.1.20.3.2 Deals 390
13.2 OTHER PLAYERS 391
13.2.1 GOOGLE LLC 391
13.2.2 AMAZON WEB SERVICES, INC. 392
13.2.3 VEEVA SYSTEMS 393
13.2.4 ELSEVIER 394
13.2.5 KOMODO HEALTH, INC. 395
14 APPENDIX 396
14.1 DISCUSSION GUIDE 396
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 401
14.3 CUSTOMIZATION OPTIONS 403
14.4 RELATED REPORTS 403
14.5 AUTHOR DETAILS 404
LIST OF TABLES
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 40
TABLE 2 LIFE SCIENCE ANALYTICS MARKET: RISK ASSESSMENT 53
TABLE 3 MARKET DYNAMICS: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN AI IN TELEHEALTH &
TELEMEDICINE MARKET 63
TABLE 4 PHARMACEUTICAL COMPANIES IMPACTED BY CYBER INCIDENTS, 2024 70
TABLE 5 LIFE SCIENCE ANALYTICS MARKET: ROLE IN ECOSYSTEM 81
TABLE 6 LIFE SCIENCE ANALYTICS MARKET: PORTER’S FIVE FORCES 84
TABLE 7 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS (%) 86
TABLE 8 KEY BUYING CRITERIA FOR END USERS 87
TABLE 9 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 90
TABLE 10 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 91
TABLE 11 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 91
TABLE 12 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 92
TABLE 13 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
TABLE 14 AVERAGE SELLING PRICE OF LIFE SCIENCE ANALYTICS SOLUTIONS,
BY APPLICATION 96
TABLE 15 AVERAGE SELLING PRICE OF ANALYTICS SOLUTIONS, BY REGION 96
TABLE 16 LIFE SCIENCE ANALYTICS MARKET: LIST OF KEY CONFERENCES AND EVENTS 97
TABLE 17 LIST OF PATENTS/PATENT APPLICATIONS 101
TABLE 18 UNMET NEEDS IN LIFE SCIENCE ANALYTICS MARKET 102
TABLE 19 END-USER EXPECTATIONS IN LIFE SCIENCE ANALYTICS MARKET 103
TABLE 20 MAJOR INVESTMENTS IN AI IN LIFE SCIENCE ANALYTICS MARKET 106
TABLE 21 US-ADJUSTED RECIPROCAL TARIFF RATES 118
TABLE 22 LIFE SCIENCE ANALYTICS MARKET, BY TYPE, 2023–2030 (USD MILLION) 124
TABLE 23 DESCRIPTIVE ANALYTICS: LIFE SCIENCE ANALYTICS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 125
TABLE 24 PREDICTIVE ANALYTICS: LIFE SCIENCE ANALYTICS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 127
TABLE 25 PRESCRIPTIVE ANALYTICS: LIFE SCIENCE ANALYTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 128
TABLE 26 LIFE SCIENCE ANALYTICS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 130
TABLE 27 LIFE SCIENCE ANALYTICS MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 131
TABLE 28 LIFE SCIENCE ANALYTICS MARKET FOR SERVICES, BY COUNTRY,
2023–2030 (USD MILLION) 131
TABLE 29 LIFE SCIENCE ANALYTICS MARKET, BY MANAGED SERVICE TYPE,
2023–2030 (USD MILLION) 132
TABLE 30 LIFE SCIENCE ANALYTICS MARKET FOR MANAGED SERVICES, BY COUNTRY,
2023–2030 (USD MILLION) 133
TABLE 31 LIFE SCIENCE ANALYTICS MARKET FOR ANALYTICAL SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 32 LIFE SCIENCE ANALYTICS MARKET FOR CONSULTING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 135
TABLE 33 LIFE SCIENCE ANALYTICS MARKET, BY PROFESSIONAL SERVICE TYPE,
2023–2030 (USD MILLION) 136
TABLE 34 LIFE SCIENCE ANALYTICS MARKET FOR PROFESSIONAL SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 137
TABLE 35 LIFE SCIENCE ANALYTICS MARKET FOR TRAINING & IMPLEMENTATION SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 138
TABLE 36 LIFE SCIENCE ANALYTICS MARKET FOR MAINTENANCE & SUPPORT SERVICES,
BY COUNTRY, 2023–2030 (USD MILLION) 139
TABLE 37 LIFE SCIENCE ANALYTICS MARKET FOR OTHER PROFESSIONAL SERVICES,
BY COUNTRY, 2023–2030 (USD MILLION) 140
TABLE 38 LIFE SCIENCE ANALYTICS MARKET, BY SOFTWARE TYPE,
2023–2030 (USD MILLION) 141
TABLE 39 LIFE SCIENCE ANALYTICS MARKET FOR SOFTWARE, BY COUNTRY,
2023–2030 (USD MILLION) 142
TABLE 40 LIFE SCIENCE ANALYTICS MARKET FOR ON-PREMISES, BY COUNTRY,
2023–2030 (USD MILLION) 143
TABLE 41 LIFE SCIENCE ANALYTICS MARKET FOR CLOUD-BASED, BY COUNTRY,
2023–2030 (USD MILLION) 145
TABLE 42 LIFE SCIENCE ANALYTICS MARKET FOR SAAS-BASED, BY COUNTRY,
2023–2030 (USD MILLION) 146
TABLE 43 LIFE SCIENCE ANALYTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 148
TABLE 44 LIFE SCIENCE ANALYTICS MARKET: COMMERCIALLY AVAILABLE R&D SOLUTIONS 149
TABLE 45 LIFE SCIENCE ANALYTICS MARKET, BY RESEARCH & DEVELOPMENT APPLICATION TYPE, 2023–2030 (USD MILLION) 150
TABLE 46 LIFE SCIENCE ANALYTICS MARKET FOR RESEARCH & DEVELOPMENT,
BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 47 LIFE SCIENCE ANALYTICS MARKET: COMMERCIALLY AVAILABLE CLINICAL
TRIAL SOLUTIONS 151
TABLE 48 LIFE SCIENCE ANALYTICS MARKET FOR CLINICAL TRIALS, BY COUNTRY,
2023–2030 (USD MILLION) 152
TABLE 49 LIFE SCIENCE ANALYTICS MARKET, BY CLINICAL TRIAL TYPE,
2023–2030 (USD MILLION) 152
TABLE 50 LIFE SCIENCE ANALYTICS MARKET FOR LABORATORY SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 153
TABLE 51 LIFE SCIENCE ANALYTICS MARKET FOR PATIENT RECRUITMENT SERVICES,
BY COUNTRY, 2023–2030 (USD MILLION) 154
TABLE 52 LIFE SCIENCE ANALYTICS MARKET FOR SITE IDENTIFICATION SERVICES,
BY COUNTRY, 2023–2030 (USD MILLION) 155
TABLE 53 LIFE SCIENCE ANALYTICS MARKET FOR OTHER CLINICAL TRIAL SERVICES,
BY COUNTRY, 2023–2030 (USD MILLION) 157
TABLE 54 LIFE SCIENCE ANALYTICS MARKET FOR CLINICAL TRIALS, BY PHASE,
2023–2030 (USD MILLION) 158
TABLE 55 LIFE SCIENCE ANALYTICS MARKET FOR PHASE I CLINICAL TRIALS,
BY COUNTRY, 2023–2030 (USD MILLION) 159
TABLE 56 LIFE SCIENCE ANALYTICS MARKET FOR PHASE II CLINICAL TRIALS,
BY COUNTRY, 2023–2030 (USD MILLION) 160
TABLE 57 LIFE SCIENCE ANALYTICS MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2023–2030 (USD MILLION) 161
TABLE 58 LIFE SCIENCE ANALYTICS MARKET: COMMERCIALLY AVAILABLE PRECLINICAL & DRUG DISCOVERY SOLUTIONS 162
TABLE 59 LIFE SCIENCE ANALYTICS MARKET FOR PRECLINICAL & DRUG DISCOVERY,
BY COUNTRY, 2023–2030 (USD MILLION) 163
TABLE 60 LIFE SCIENCE ANALYTICS MARKET, BY COMMERCIAL ANALYTICS APPLICATION TYPE, 2023–2030 (USD MILLION) 164
TABLE 61 LIFE SCIENCE ANALYTICS MARKET FOR COMMERCIAL ANALYTICS, BY COUNTRY, 2023–2030 (USD MILLION) 164
TABLE 62 LIFE SCIENCE ANALYTICS MARKET: COMMERCIALLY AVAILABLE
SALES & MARKETING SOLUTIONS 165
TABLE 63 LIFE SCIENCE ANALYTICS MARKET FOR SALES & MARKETING SUPPORT,
BY COUNTRY, 2023–2030 (USD MILLION) 166
TABLE 64 LIFE SCIENCE ANALYTICS MARKET FOR MARKET ACCESS, BY COUNTRY,
2023–2030 (USD MILLION) 167
TABLE 65 LIFE SCIENCE ANALYTICS MARKET FOR RWE & VALUE EVIDENCE, BY COUNTRY, 2023–2030 (USD MILLION) 168
TABLE 66 LIFE SCIENCE ANALYTICS MARKET FOR ENGAGEMENT SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 169
TABLE 67 LIFE SCIENCE ANALYTICS MARKET: COMMERCIALLY AVAILABLE REGULATORY COMPLIANCE SOLUTIONS 170
TABLE 68 LIFE SCIENCE ANALYTICS MARKET FOR REGULATORY COMPLIANCE, BY COUNTRY, 2023–2030 (USD MILLION) 171
TABLE 69 LIFE SCIENCE ANALYTICS MARKET: COMMERCIALLY AVAILABLE MANUFACTURING & SUPPLY CHAIN OPTIMIZATION SOLUTIONS 172
TABLE 70 LIFE SCIENCE ANALYTICS MARKET FOR MANUFACTURING & SUPPLY CHAIN OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 172
TABLE 71 LIFE SCIENCE ANALYTICS MARKET, BY SAFETY APPLICATION TYPE,
2023–2030 (USD MILLION) 173
TABLE 72 LIFE SCIENCE ANALYTICS MARKET FOR SAFETY, BY COUNTRY,
2023–2030 (USD MILLION) 173
TABLE 73 LIFE SCIENCE ANALYTICS MARKET: COMMERCIALLY AVAILABLE PHARMACOVIGILANCE SOLUTIONS 174
TABLE 74 LIFE SCIENCE ANALYTICS MARKET FOR PHARMACOVIGILANCE, BY COUNTRY, 2023–2030 (USD MILLION) 175
TABLE 75 LIFE SCIENCE ANALYTICS MARKET FOR MEDICAL DEVICE SAFETY, BY COUNTRY, 2023–2030 (USD MILLION) 176
TABLE 76 LIFE SCIENCE ANALYTICS MARKET FOR DIAGNOSTIC VIGILANCE, BY COUNTRY, 2023–2030 (USD MILLION) 177
TABLE 77 LIFE SCIENCE ANALYTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 179
TABLE 78 LIFE SCIENCE ANALYTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 180
TABLE 79 LIFE SCIENCE ANALYTICS MARKET FOR MEDICAL DEVICE COMPANIES,
BY COUNTRY, 2023–2030 (USD MILLION) 181
TABLE 80 LIFE SCIENCE ANALYTICS MARKET FOR RESEARCH CENTERS, BY COUNTRY,
2023–2030 (USD MILLION) 182
TABLE 81 LIFE SCIENCE ANALYTICS MARKET FOR OUTSOURCED LIFE SCIENCE ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 183
TABLE 82 LIFE SCIENCE ANALYTICS MARKET, BY REGION, 2023–2030 (USD MILLION) 185
TABLE 83 NORTH AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 187
TABLE 84 NORTH AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY TYPE,
2023–2030 (USD MILLION) 188
TABLE 85 NORTH AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 188
TABLE 86 NORTH AMERICA: LIFE SCIENCE ANALYTICS SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 188
TABLE 87 NORTH AMERICA: MANAGED SERVICES MARKET, BY MANAGED SERVICE TYPE, 2023–2030 (USD MILLION) 189
TABLE 88 NORTH AMERICA: PROFESSIONAL SERVICES MARKET, BY PROFESSIONAL SERVICE TYPE, 2023–2030 (USD MILLION) 189
TABLE 89 NORTH AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY SOFTWARE TYPE,
2023–2030 (USD MILLION) 189
TABLE 90 NORTH AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 190
TABLE 91 NORTH AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY RESEARCH & DEVELOPMENT APPLICATION TYPE, 2023–2030 (USD MILLION) 190
TABLE 92 NORTH AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY CLINICAL TRIAL TYPE, 2023–2030 (USD MILLION) 190
TABLE 93 NORTH AMERICA: LIFE SCIENCE ANALYTICS MARKET FOR CLINICAL TRIALS,
BY PHASE, 2023–2030 (USD MILLION) 191
TABLE 94 NORTH AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY COMMERCIAL ANALYTICS APPLICATION TYPE, 2023–2030 (USD MILLION) 191
TABLE 95 NORTH AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY SAFETY APPLICATION TYPE, 2023–2030 (USD MILLION) 191
TABLE 96 NORTH AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 192
TABLE 97 US: LIFE SCIENCE ANALYTICS MARKET, BY TYPE, 2023–2030 (USD MILLION) 193
TABLE 98 US: LIFE SCIENCE ANALYTICS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 193
TABLE 99 US: LIFE SCIENCE ANALYTICS SERVICES MARKET, BY SERVICE TYPE,
2023–2030 (USD MILLION) 193
TABLE 100 US: MANAGED SERVICES MARKET, BY MANAGED SERVICE TYPE,
2023–2030 (USD MILLION) 194
TABLE 101 US: PROFESSIONAL SERVICES MARKET, BY PROFESSIONAL SERVICE TYPE,
2023–2030 (USD MILLION) 194
TABLE 102 US: LIFE SCIENCE ANALYTICS SOFTWARE MARKET, BY SOFTWARE TYPE,
2023–2030 (USD MILLION) 194
TABLE 103 US: LIFE SCIENCE ANALYTICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 195
TABLE 104 US: LIFE SCIENCE ANALYTICS MARKET, BY RESEARCH & DEVELOPMENT APPLICATION TYPE, 2023–2030 (USD MILLION) 195
TABLE 105 US: LIFE SCIENCE ANALYTICS MARKET, BY CLINICAL TRIAL TYPE,
2023–2030 (USD MILLION) 195
TABLE 106 US: LIFE SCIENCE ANALYTICS MARKET FOR CLINICAL TRIALS, BY PHASE,
2023–2030 (USD MILLION) 196
TABLE 107 US: LIFE SCIENCE ANALYTICS MARKET, BY COMMERCIAL ANALYTICS APPLICATION TYPE, 2023–2030 (USD MILLION) 196
TABLE 108 US: LIFE SCIENCE ANALYTICS MARKET, BY SAFETY APPLICATION TYPE,
2023–2030 (USD MILLION) 196
TABLE 109 US: LIFE SCIENCE ANALYTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 197
TABLE 110 CANADA: LIFE SCIENCE ANALYTICS MARKET, BY TYPE, 2023–2030 (USD MILLION) 198
TABLE 111 CANADA: LIFE SCIENCE ANALYTICS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 198
TABLE 112 CANADA: LIFE SCIENCE ANALYTICS MARKET, BY SERVICES TYPE,
2023–2030 (USD MILLION) 198
TABLE 113 CANADA: LIFE SCIENCE ANALYTICS MARKET, BY MANAGED SERVICE TYPE,
2023–2030 (USD MILLION) 199
TABLE 114 CANADA: LIFE SCIENCE ANALYTICS MARKET, BY PROFESSIONAL SERVICE TYPE, 2023–2030 (USD MILLION) 199
TABLE 115 CANADA: LIFE SCIENCE ANALYTICS MARKET, BY SOFTWARE TYPE,
2023–2030 (USD MILLION) 199
TABLE 116 CANADA: LIFE SCIENCE ANALYTICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 200
TABLE 117 CANADA: LIFE SCIENCE ANALYTICS MARKET, BY RESEARCH & DEVELOPMENT APPLICATION TYPE, 2023–2030 (USD MILLION) 200
TABLE 118 CANADA: LIFE SCIENCE ANALYTICS MARKET, BY CLINICAL TRIAL TYPE,
2023–2030 (USD MILLION) 200
TABLE 119 CANADA: LIFE SCIENCE ANALYTICS MARKET FOR CLINICAL TRIALS, BY PHASE, 2023–2030 (USD MILLION) 201
TABLE 120 CANADA: LIFE SCIENCE ANALYTICS MARKET, BY COMMERCIAL ANALYTICS APPLICATION TYPE, 2023–2030 (USD MILLION) 201
TABLE 121 CANADA: LIFE SCIENCE ANALYTICS MARKET, BY SAFETY APPLICATION TYPE, 2023–2030 (USD MILLION) 201
TABLE 122 CANADA: LIFE SCIENCE ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 202
TABLE 123 EUROPE: LIFE SCIENCE ANALYTICS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 203
TABLE 124 EUROPE: LIFE SCIENCE ANALYTICS MARKET, BY TYPE, 2023–2030 (USD MILLION) 203
TABLE 125 EUROPE: LIFE SCIENCE ANALYTICS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 204
TABLE 126 EUROPE: LIFE SCIENCE ANALYTICS MARKET, BY SERVICE TYPE,
2023–2030 (USD MILLION) 204
TABLE 127 EUROPE: LIFE SCIENCE ANALYTICS MARKET, BY MANAGED SERVICE TYPE,
2023–2030 (USD MILLION) 204
TABLE 128 EUROPE: LIFE SCIENCE ANALYTICS MARKET, BY PROFESSIONAL SERVICE TYPE, 2023–2030 (USD MILLION) 205
TABLE 129 EUROPE: LIFE SCIENCE ANALYTICS MARKET, BY SOFTWARE TYPE,
2023–2030 (USD MILLION) 205
TABLE 130 EUROPE: LIFE SCIENCE ANALYTICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 205
TABLE 131 EUROPE: LIFE SCIENCE ANALYTICS MARKET, BY RESEARCH & DEVELOPMENT APPLICATION TYPE, 2023–2030 (USD MILLION) 206
TABLE 132 EUROPE: LIFE SCIENCE ANALYTICS MARKET, BY CLINICAL TRIAL TYPE,
2023–2030 (USD MILLION) 206
TABLE 133 EUROPE: LIFE SCIENCE ANALYTICS MARKET FOR CLINICAL TRIALS, BY PHASE, 2023–2030 (USD MILLION) 206
TABLE 134 EUROPE: LIFE SCIENCE ANALYTICS MARKET, BY COMMERCIAL ANALYTICS APPLICATION TYPE, 2023–2030 (USD MILLION) 207
TABLE 135 EUROPE: LIFE SCIENCE ANALYTICS MARKET, BY SAFETY APPLICATION TYPE, 2023–2030 (USD MILLION) 207
TABLE 136 EUROPE: LIFE SCIENCE ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 207
TABLE 137 GERMANY: LIFE SCIENCE ANALYTICS MARKET, BY TYPE,
2023–2030 (USD MILLION) 208
TABLE 138 GERMANY: LIFE SCIENCE ANALYTICS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 209
TABLE 139 GERMANY: LIFE SCIENCE ANALYTICS MARKET, BY SERVICE TYPE,
2023–2030 (USD MILLION) 209
TABLE 140 GERMANY: LIFE SCIENCE ANALYTICS MARKET, BY MANAGED SERVICE TYPE, 2023–2030 (USD MILLION) 209
TABLE 141 GERMANY: LIFE SCIENCE ANALYTICS MARKET, BY PROFESSIONAL SERVICE TYPE, 2023–2030 (USD MILLION) 210
TABLE 142 GERMANY: LIFE SCIENCE ANALYTICS MARKET, BY SOFTWARE TYPE,
2023–2030 (USD MILLION) 210
TABLE 143 GERMANY: LIFE SCIENCE ANALYTICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 210
TABLE 144 GERMANY: LIFE SCIENCE ANALYTICS MARKET, BY RESEARCH & DEVELOPMENT APPLICATION TYPE, 2023–2030 (USD MILLION) 211
TABLE 145 GERMANY: LIFE SCIENCE ANALYTICS MARKET, BY CLINICAL TRIAL TYPE,
2023–2030 (USD MILLION) 211
TABLE 146 GERMANY: LIFE SCIENCE ANALYTICS MARKET FOR CLINICAL TRIALS, BY PHASE, 2023–2030 (USD MILLION) 211
TABLE 147 GERMANY: LIFE SCIENCE ANALYTICS MARKET, BY COMMERCIAL ANALYTICS APPLICATION TYPE, 2023–2030 (USD MILLION) 212
TABLE 148 GERMANY: LIFE SCIENCE ANALYTICS MARKET, BY SAFETY APPLICATION TYPE, 2023–2030 (USD MILLION) 212
TABLE 149 GERMANY: LIFE SCIENCE ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 212
TABLE 150 FRANCE: LIFE SCIENCE ANALYTICS MARKET, BY TYPE, 2023–2030 (USD MILLION) 213
TABLE 151 FRANCE: LIFE SCIENCE ANALYTICS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 214
TABLE 152 FRANCE: LIFE SCIENCE ANALYTICS MARKET, BY SERVICE TYPE,
2023–2030 (USD MILLION) 214
TABLE 153 FRANCE: LIFE SCIENCE ANALYTICS MARKET, BY MANAGED SERVICE TYPE,
2023–2030 (USD MILLION) 214
TABLE 154 FRANCE: LIFE SCIENCE ANALYTICS MARKET, BY PROFESSIONAL SERVICE TYPE, 2023–2030 (USD MILLION) 215
TABLE 155 FRANCE: LIFE SCIENCE ANALYTICS MARKET, BY SOFTWARE TYPE,
2023–2030 (USD MILLION) 215
TABLE 156 FRANCE: LIFE SCIENCE ANALYTICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 215
TABLE 157 FRANCE: LIFE SCIENCE ANALYTICS MARKET, BY RESEARCH & DEVELOPMENT APPLICATION TYPE, 2023–2030 (USD MILLION) 216
TABLE 158 FRANCE: LIFE SCIENCE ANALYTICS MARKET, BY CLINICAL TRIAL TYPE,
2023–2030 (USD MILLION) 216
TABLE 159 FRANCE: LIFE SCIENCE ANALYTICS MARKET FOR CLINICAL TRIALS, BY PHASE, 2023–2030 (USD MILLION) 216
TABLE 160 FRANCE: LIFE SCIENCE ANALYTICS MARKET, BY COMMERCIAL ANALYTICS APPLICATION TYPE, 2023–2030 (USD MILLION) 217
TABLE 161 FRANCE: LIFE SCIENCE ANALYTICS MARKET, BY SAFETY APPLICATION TYPE,
2023–2030 (USD MILLION) 217
TABLE 162 FRANCE: LIFE SCIENCE ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 217
TABLE 163 UK: LIFE SCIENCE ANALYTICS MARKET, BY TYPE, 2023–2030 (USD MILLION) 218
TABLE 164 UK: LIFE SCIENCE ANALYTICS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 218
TABLE 165 UK: LIFE SCIENCE ANALYTICS MARKET, BY SERVICE TYPE,
2023–2030 (USD MILLION) 219
TABLE 166 UK: LIFE SCIENCE ANALYTICS MARKET, BY MANAGED SERVICE TYPE,
2023–2030 (USD MILLION) 219
TABLE 167 UK: LIFE SCIENCE ANALYTICS MARKET, BY PROFESSIONAL SERVICE TYPE,
2023–2030 (USD MILLION) 219
TABLE 168 UK: LIFE SCIENCE ANALYTICS MARKET, BY SOFTWARE TYPE,
2023–2030 (USD MILLION) 220
TABLE 169 UK: LIFE SCIENCE ANALYTICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 220
TABLE 170 UK: LIFE SCIENCE ANALYTICS MARKET, BY RESEARCH & DEVELOPMENT APPLICATION TYPE, 2023–2030 (USD MILLION) 220
TABLE 171 UK: LIFE SCIENCE ANALYTICS MARKET, BY CLINICAL TRIAL TYPE,
2023–2030 (USD MILLION) 221
TABLE 172 UK: LIFE SCIENCE ANALYTICS MARKET FOR CLINICAL TRIALS, BY PHASE,
2023–2030 (USD MILLION) 221
TABLE 173 UK: LIFE SCIENCE ANALYTICS MARKET, BY COMMERCIAL ANALYTICS APPLICATION TYPE, 2023–2030 (USD MILLION) 221
TABLE 174 UK: LIFE SCIENCE ANALYTICS MARKET, BY SAFETY APPLICATION TYPE,
2023–2030 (USD MILLION) 222
TABLE 175 UK: LIFE SCIENCE ANALYTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 222
TABLE 176 ITALY: LIFE SCIENCE ANALYTICS MARKET, BY TYPE, 2023–2030 (USD MILLION) 223
TABLE 177 ITALY: LIFE SCIENCE ANALYTICS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 223
TABLE 178 ITALY: LIFE SCIENCE ANALYTICS MARKET, BY SERVICE TYPE,
2023–2030 (USD MILLION) 223
TABLE 179 ITALY: LIFE SCIENCE ANALYTICS MARKET, BY MANAGED SERVICE TYPE,
2023–2030 (USD MILLION) 224
TABLE 180 ITALY: LIFE SCIENCE ANALYTICS MARKET, BY PROFESSIONAL SERVICE TYPE, 2023–2030 (USD MILLION) 224
TABLE 181 ITALY: LIFE SCIENCE ANALYTICS MARKET, BY SOFTWARE TYPE,
2023–2030 (USD MILLION) 224
TABLE 182 ITALY: LIFE SCIENCE ANALYTICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 225
TABLE 183 ITALY: LIFE SCIENCE ANALYTICS MARKET, BY RESEARCH & DEVELOPMENT APPLICATION TYPE, 2023–2030 (USD MILLION) 225
TABLE 184 ITALY: LIFE SCIENCE ANALYTICS MARKET, BY CLINICAL TRIAL TYPE,
2023–2030 (USD MILLION) 225
TABLE 185 ITALY: LIFE SCIENCE ANALYTICS MARKET FOR CLINICAL TRIALS, BY PHASE,
2023–2030 (USD MILLION) 226
TABLE 186 ITALY: LIFE SCIENCE ANALYTICS MARKET, BY COMMERCIAL ANALYTICS APPLICATION TYPE, 2023–2030 (USD MILLION) 226
TABLE 187 ITALY: LIFE SCIENCE ANALYTICS MARKET, BY SAFETY APPLICATION TYPE,
2023–2030 (USD MILLION) 226
TABLE 188 ITALY: LIFE SCIENCE ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 227
TABLE 189 SPAIN: LIFE SCIENCE ANALYTICS MARKET, BY TYPE, 2023–2030 (USD MILLION) 227
TABLE 190 SPAIN: LIFE SCIENCE ANALYTICS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 228
TABLE 191 SPAIN: LIFE SCIENCE ANALYTICS MARKET, BY SERVICE TYPE,
2023–2030 (USD MILLION) 228
TABLE 192 SPAIN: LIFE SCIENCE ANALYTICS MARKET, BY MANAGED SERVICE TYPE,
2023–2030 (USD MILLION) 228
TABLE 193 SPAIN: LIFE SCIENCE ANALYTICS MARKET, BY PROFESSIONAL SERVICE TYPE, 2023–2030 (USD MILLION) 229
TABLE 194 SPAIN: LIFE SCIENCE ANALYTICS MARKET, BY SOFTWARE TYPE,
2023–2030 (USD MILLION) 229
TABLE 195 SPAIN: LIFE SCIENCE ANALYTICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 229
TABLE 196 SPAIN: LIFE SCIENCE ANALYTICS MARKET, BY RESEARCH & DEVELOPMENT APPLICATION TYPE, 2023–2030 (USD MILLION) 230
TABLE 197 SPAIN: LIFE SCIENCE ANALYTICS MARKET, BY CLINICAL TRIAL TYPE,
2023–2030 (USD MILLION) 230
TABLE 198 SPAIN: LIFE SCIENCE ANALYTICS MARKET FOR CLINICAL TRIALS, BY PHASE,
2023–2030 (USD MILLION) 230
TABLE 199 SPAIN: LIFE SCIENCE ANALYTICS MARKET, BY COMMERCIAL ANALYTICS APPLICATION TYPE, 2023–2030 (USD MILLION) 231
TABLE 200 SPAIN: LIFE SCIENCE ANALYTICS MARKET, BY SAFETY APPLICATION TYPE,
2023–2030 (USD MILLION) 231
TABLE 201 SPAIN: LIFE SCIENCE ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 231
TABLE 202 REST OF EUROPE: LIFE SCIENCE ANALYTICS MARKET, BY TYPE,
2023–2030 (USD MILLION) 232
TABLE 203 REST OF EUROPE: LIFE SCIENCE ANALYTICS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 232
TABLE 204 REST OF EUROPE: LIFE SCIENCE ANALYTICS MARKET, BY SERVICE TYPE,
2023–2030 (USD MILLION) 233
TABLE 205 REST OF EUROPE: LIFE SCIENCE ANALYTICS MARKET, BY MANAGED SERVICE TYPE, 2023–2030 (USD MILLION) 233
TABLE 206 REST OF EUROPE: LIFE SCIENCE ANALYTICS MARKET, BY PROFESSIONAL SERVICE TYPE, 2023–2030 (USD MILLION) 233
TABLE 207 REST OF EUROPE: LIFE SCIENCE ANALYTICS MARKET, BY SOFTWARE TYPE,
2023–2030 (USD MILLION) 234
TABLE 208 REST OF EUROPE: LIFE SCIENCE ANALYTICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 234
TABLE 209 REST OF EUROPE: LIFE SCIENCE ANALYTICS MARKET, BY RESEARCH & DEVELOPMENT APPLICATION TYPE, 2023–2030 (USD MILLION) 234
TABLE 210 REST OF EUROPE: LIFE SCIENCE ANALYTICS MARKET, BY CLINICAL TRIAL TYPE, 2023–2030 (USD MILLION) 235
TABLE 211 REST OF EUROPE: LIFE SCIENCE ANALYTICS MARKET FOR CLINICAL TRIALS,
BY PHASE, 2023–2030 (USD MILLION) 235
TABLE 212 REST OF EUROPE: LIFE SCIENCE ANALYTICS MARKET, BY COMMERCIAL ANALYTICS APPLICATION TYPE, 2023–2030 (USD MILLION) 235
TABLE 213 REST OF EUROPE: LIFE SCIENCE ANALYTICS MARKET, BY SAFETY APPLICATION TYPE, 2023–2030 (USD MILLION) 236
TABLE 214 REST OF EUROPE: LIFE SCIENCE ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 236
TABLE 215 ASIA PACIFIC: LIFE SCIENCE ANALYTICS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 239
TABLE 216 ASIA PACIFIC: LIFE SCIENCE ANALYTICS MARKET, BY TYPE,
2023–2030 (USD MILLION) 239
TABLE 217 ASIA PACIFIC: LIFE SCIENCE ANALYTICS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 239
TABLE 218 ASIA PACIFIC: LIFE SCIENCE ANALYTICS MARKET, BY SERVICE TYPE,
2023–2030 (USD MILLION) 240
TABLE 219 ASIA PACIFIC: LIFE SCIENCE ANALYTICS MARKET, BY MANAGED SERVICE TYPE, 2023–2030 (USD MILLION) 240
TABLE 220 ASIA PACIFIC: LIFE SCIENCE ANALYTICS MARKET, BY PROFESSIONAL SERVICE TYPE, 2023–2030 (USD MILLION) 240
TABLE 221 ASIA PACIFIC: LIFE SCIENCE ANALYTICS MARKET, BY SOFTWARE TYPE,
2023–2030 (USD MILLION) 241
TABLE 222 ASIA PACIFIC: LIFE SCIENCE ANALYTICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 241
TABLE 223 ASIA PACIFIC: LIFE SCIENCE ANALYTICS MARKET, BY RESEARCH & DEVELOPMENT APPLICATION TYPE, 2023–2030 (USD MILLION) 241
TABLE 224 ASIA PACIFIC: LIFE SCIENCE ANALYTICS MARKET, BY CLINICAL TRIAL TYPE,
2023–2030 (USD MILLION) 242
TABLE 225 ASIA PACIFIC: LIFE SCIENCE ANALYTICS MARKET FOR CLINICAL TRIALS, BY PHASE, 2023–2030 (USD MILLION) 242
TABLE 226 ASIA PACIFIC: LIFE SCIENCE ANALYTICS MARKET, BY COMMERCIAL ANALYTICS APPLICATION TYPE, 2023–2030 (USD MILLION) 242
TABLE 227 ASIA PACIFIC: LIFE SCIENCE ANALYTICS MARKET, BY SAFETY APPLICATION TYPE, 2023–2030 (USD MILLION) 243
TABLE 228 ASIA PACIFIC: LIFE SCIENCE ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 243
TABLE 229 JAPAN: LIFE SCIENCE ANALYTICS MARKET, BY TYPE, 2023–2030 (USD MILLION) 244
TABLE 230 JAPAN: LIFE SCIENCE ANALYTICS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 244
TABLE 231 JAPAN: LIFE SCIENCE ANALYTICS MARKET, BY SERVICE TYPE,
2023–2030 (USD MILLION) 245
TABLE 232 JAPAN: LIFE SCIENCE ANALYTICS MARKET, BY MANAGED SERVICE TYPE,
2023–2030 (USD MILLION) 245
TABLE 233 JAPAN: LIFE SCIENCE ANALYTICS MARKET, BY PROFESSIONAL SERVICE TYPE, 2023–2030 (USD MILLION) 245
TABLE 234 JAPAN: LIFE SCIENCE ANALYTICS MARKET, BY SOFTWARE TYPE,
2023–2030 (USD MILLION) 246
TABLE 235 JAPAN: LIFE SCIENCE ANALYTICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 246
TABLE 236 JAPAN: LIFE SCIENCE ANALYTICS MARKET, BY RESEARCH & DEVELOPMENT APPLICATION TYPE, 2023–2030 (USD MILLION) 246
TABLE 237 JAPAN: LIFE SCIENCE ANALYTICS MARKET, BY CLINICAL TRIAL TYPE,
2023–2030 (USD MILLION) 247
TABLE 238 JAPAN: LIFE SCIENCE ANALYTICS MARKET FOR CLINICAL TRIALS, BY PHASE, 2023–2030 (USD MILLION) 247
TABLE 239 JAPAN: LIFE SCIENCE ANALYTICS MARKET, BY COMMERCIAL ANALYTICS APPLICATION TYPE, 2023–2030 (USD MILLION) 247
TABLE 240 JAPAN: LIFE SCIENCE ANALYTICS MARKET, BY SAFETY APPLICATION TYPE,
2023–2030 (USD MILLION) 248
TABLE 241 JAPAN: LIFE SCIENCE ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 248
TABLE 242 CHINA: LIFE SCIENCE ANALYTICS MARKET, BY TYPE, 2023–2030 (USD MILLION) 249
TABLE 243 CHINA: LIFE SCIENCE ANALYTICS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 249
TABLE 244 CHINA: LIFE SCIENCE ANALYTICS MARKET, BY SERVICE TYPE,
2023–2030 (USD MILLION) 249
TABLE 245 CHINA: LIFE SCIENCE ANALYTICS MARKET, BY MANAGED SERVICE TYPE,
2023–2030 (USD MILLION) 250
TABLE 246 CHINA: LIFE SCIENCE ANALYTICS MARKET, BY PROFESSIONAL SERVICE TYPE, 2023–2030 (USD MILLION) 250
TABLE 247 CHINA: LIFE SCIENCE ANALYTICS MARKET, BY SOFTWARE TYPE,
2023–2030 (USD MILLION) 250
TABLE 248 CHINA: LIFE SCIENCE ANALYTICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 251
TABLE 249 CHINA: LIFE SCIENCE ANALYTICS MARKET, BY RESEARCH & DEVELOPMENT APPLICATION TYPE, 2023–2030 (USD MILLION) 251
TABLE 250 CHINA: LIFE SCIENCE ANALYTICS MARKET, BY CLINICAL TRIAL TYPE,
2023–2030 (USD MILLION) 251
TABLE 251 CHINA: LIFE SCIENCE ANALYTICS MARKET FOR CLINICAL TRIALS, BY PHASE, 2023–2030 (USD MILLION) 252
TABLE 252 CHINA: LIFE SCIENCE ANALYTICS MARKET, BY COMMERCIAL ANALYTICS APPLICATION TYPE, 2023–2030 (USD MILLION) 252
TABLE 253 CHINA: LIFE SCIENCE ANALYTICS MARKET, BY SAFETY APPLICATION TYPE,
2023–2030 (USD MILLION) 252
TABLE 254 CHINA: LIFE SCIENCE ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 253
TABLE 255 INDIA: LIFE SCIENCE ANALYTICS MARKET, BY TYPE, 2023–2030 (USD MILLION) 254
TABLE 256 INDIA: LIFE SCIENCE ANALYTICS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 254
TABLE 257 INDIA: LIFE SCIENCE ANALYTICS MARKET, BY SERVICE TYPE,
2023–2030 (USD MILLION) 254
TABLE 258 INDIA: LIFE SCIENCE ANALYTICS MARKET, BY MANAGED SERVICE TYPE,
2023–2030 (USD MILLION) 255
TABLE 259 INDIA: LIFE SCIENCE ANALYTICS MARKET, BY PROFESSIONAL SERVICE TYPE, 2023–2030 (USD MILLION) 255
TABLE 260 INDIA: LIFE SCIENCE ANALYTICS MARKET, BY SOFTWARE TYPE,
2023–2030 (USD MILLION) 255
TABLE 261 INDIA: LIFE SCIENCE ANALYTICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 256
TABLE 262 INDIA: LIFE SCIENCE ANALYTICS MARKET, BY RESEARCH & DEVELOPMENT APPLICATION TYPE, 2023–2030 (USD MILLION) 256
TABLE 263 INDIA: LIFE SCIENCE ANALYTICS MARKET, BY CLINICAL TRIAL TYPE,
2023–2030 (USD MILLION) 256
TABLE 264 INDIA: LIFE SCIENCE ANALYTICS MARKET FOR CLINICAL TRIALS, BY PHASE,
2023–2030 (USD MILLION) 257
TABLE 265 INDIA: LIFE SCIENCE ANALYTICS MARKET, BY COMMERCIAL ANALYTICS APPLICATION TYPE, 2023–2030 (USD MILLION) 257
TABLE 266 INDIA: LIFE SCIENCE ANALYTICS MARKET, BY SAFETY APPLICATION TYPE,
2023–2030 (USD MILLION) 257
TABLE 267 INDIA: LIFE SCIENCE ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 258
TABLE 268 REST OF ASIA PACIFIC: LIFE SCIENCE ANALYTICS MARKET, BY TYPE,
2023–2030 (USD MILLION) 259
TABLE 269 REST OF ASIA PACIFIC: LIFE SCIENCE ANALYTICS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 259
TABLE 270 REST OF ASIA PACIFIC: LIFE SCIENCE ANALYTICS MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 259
TABLE 271 REST OF ASIA PACIFIC: LIFE SCIENCE ANALYTICS MARKET, BY MANAGED SERVICE TYPE, 2023–2030 (USD MILLION) 260
TABLE 272 REST OF ASIA PACIFIC: LIFE SCIENCE ANALYTICS MARKET, BY PROFESSIONAL SERVICE TYPE, 2023–2030 (USD MILLION) 260
TABLE 273 REST OF ASIA PACIFIC: LIFE SCIENCE ANALYTICS MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION) 260
TABLE 274 REST OF ASIA PACIFIC: LIFE SCIENCE ANALYTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 261
TABLE 275 REST OF ASIA PACIFIC: LIFE SCIENCE ANALYTICS MARKET, BY RESEARCH & DEVELOPMENT APPLICATION TYPE, 2023–2030 (USD MILLION) 261
TABLE 276 REST OF ASIA PACIFIC: LIFE SCIENCE ANALYTICS MARKET, BY CLINICAL TRIAL TYPE, 2023–2030 (USD MILLION) 261
TABLE 277 REST OF ASIA PACIFIC: LIFE SCIENCE ANALYTICS MARKET FOR CLINICAL TRIALS, BY PHASE, 2023–2030 (USD MILLION) 262
TABLE 278 REST OF ASIA PACIFIC: LIFE SCIENCE ANALYTICS MARKET, BY COMMERCIAL ANALYTICS APPLICATION TYPE, 2023–2030 (USD MILLION) 262
TABLE 279 REST OF ASIA PACIFIC: LIFE SCIENCE ANALYTICS MARKET, BY SAFETY APPLICATION TYPE, 2023–2030 (USD MILLION) 262
TABLE 280 REST OF ASIA PACIFIC: LIFE SCIENCE ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 263
TABLE 281 LATIN AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 264
TABLE 282 LATIN AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY TYPE,
2023–2030 (USD MILLION) 264
TABLE 283 LATIN AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 264
TABLE 284 LATIN AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY SERVICE TYPE,
2023–2030 (USD MILLION) 265
TABLE 285 LATIN AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY MANAGED SERVICE TYPE, 2023–2030 (USD MILLION) 265
TABLE 286 LATIN AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY PROFESSIONAL SERVICE TYPE, 2023–2030 (USD MILLION) 265
TABLE 287 LATIN AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY SOFTWARE TYPE,
2023–2030 (USD MILLION) 266
TABLE 288 LATIN AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 266
TABLE 289 LATIN AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY RESEARCH & DEVELOPMENT APPLICATION TYPE, 2023–2030 (USD MILLION) 266
TABLE 290 LATIN AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY CLINICAL TRIAL TYPE, 2023–2030 (USD MILLION) 267
TABLE 291 LATIN AMERICA: LIFE SCIENCE ANALYTICS MARKET FOR CLINICAL TRIALS,
BY PHASE, 2023–2030 (USD MILLION) 267
TABLE 292 LATIN AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY COMMERCIAL ANALYTICS APPLICATION TYPE, 2023–2030 (USD MILLION) 267
TABLE 293 LATIN AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY SAFETY APPLICATION TYPE, 2023–2030 (USD MILLION) 268
TABLE 294 LATIN AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 268
TABLE 295 BRAZIL: LIFE SCIENCE ANALYTICS MARKET, BY TYPE, 2023–2030 (USD MILLION) 269
TABLE 296 BRAZIL: LIFE SCIENCE ANALYTICS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 269
TABLE 297 BRAZIL: LIFE SCIENCE ANALYTICS MARKET, BY SERVICE TYPE,
2023–2030 (USD MILLION) 269
TABLE 298 BRAZIL: LIFE SCIENCE ANALYTICS MARKET, BY MANAGED SERVICE TYPE,
2023–2030 (USD MILLION) 270
TABLE 299 BRAZIL: LIFE SCIENCE ANALYTICS MARKET, BY PROFESSIONAL SERVICE TYPE, 2023–2030 (USD MILLION) 270
TABLE 300 BRAZIL: LIFE SCIENCE ANALYTICS MARKET, BY SOFTWARE TYPE,
2023–2030 (USD MILLION) 270
TABLE 301 BRAZIL: LIFE SCIENCE ANALYTICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 271
TABLE 302 BRAZIL: LIFE SCIENCE ANALYTICS MARKET, BY RESEARCH & DEVELOPMENT APPLICATION TYPE, 2023–2030 (USD MILLION) 271
TABLE 303 BRAZIL: LIFE SCIENCE ANALYTICS MARKET, BY CLINICAL TRIAL TYPE,
2023–2030 (USD MILLION) 271
TABLE 304 BRAZIL: LIFE SCIENCE ANALYTICS MARKET FOR CLINICAL TRIALS, BY PHASE, 2023–2030 (USD MILLION) 272
TABLE 305 BRAZIL: LIFE SCIENCE ANALYTICS MARKET, BY COMMERCIAL ANALYTICS APPLICATION TYPE, 2023–2030 (USD MILLION) 272
TABLE 306 BRAZIL: LIFE SCIENCE ANALYTICS MARKET, BY SAFETY APPLICATION TYPE,
2023–2030 (USD MILLION) 272
TABLE 307 BRAZIL: LIFE SCIENCE ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 273
TABLE 308 MEXICO: LIFE SCIENCE ANALYTICS MARKET, BY TYPE, 2023–2030 (USD MILLION) 274
TABLE 309 MEXICO: LIFE SCIENCE ANALYTICS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 274
TABLE 310 MEXICO: LIFE SCIENCE ANALYTICS MARKET, BY SERVICE TYPE,
2023–2030 (USD MILLION) 274
TABLE 311 MEXICO: LIFE SCIENCE ANALYTICS MARKET, BY MANAGED SERVICE TYPE,
2023–2030 (USD MILLION) 275
TABLE 312 MEXICO: LIFE SCIENCE ANALYTICS MARKET, BY PROFESSIONAL SERVICE TYPE, 2023–2030 (USD MILLION) 275
TABLE 313 MEXICO: LIFE SCIENCE ANALYTICS MARKET, BY SOFTWARE TYPE,
2023–2030 (USD MILLION) 275
TABLE 314 MEXICO: LIFE SCIENCE ANALYTICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 276
TABLE 315 MEXICO: LIFE SCIENCE ANALYTICS MARKET, BY RESEARCH & DEVELOPMENT APPLICATION TYPE, 2023–2030 (USD MILLION) 276
TABLE 316 MEXICO: LIFE SCIENCE ANALYTICS MARKET, BY CLINICAL TRIAL TYPE,
2023–2030 (USD MILLION) 276
TABLE 317 MEXICO: LIFE SCIENCE ANALYTICS MARKET FOR CLINICAL TRIALS, BY PHASE, 2023–2030 (USD MILLION) 277
TABLE 318 MEXICO: LIFE SCIENCE ANALYTICS MARKET, BY COMMERCIAL ANALYTICS APPLICATION TYPE, 2023–2030 (USD MILLION) 277
TABLE 319 MEXICO: LIFE SCIENCE ANALYTICS MARKET, BY SAFETY APPLICATION TYPE,
2023–2030 (USD MILLION) 277
TABLE 320 MEXICO: LIFE SCIENCE ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 278
TABLE 321 REST OF LATIN AMERICA: LIFE SCIENCE ANALYTICS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 279
TABLE 322 REST OF LATIN AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 279
TABLE 323 REST OF LATIN AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 279
TABLE 324 REST OF LATIN AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY MANAGED SERVICE TYPE, 2023–2030 (USD MILLION) 280
TABLE 325 REST OF LATIN AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY PROFESSIONAL SERVICE TYPE, 2023–2030 (USD MILLION) 280
TABLE 326 REST OF LATIN AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION)SOFTWARE 280
TABLE 327 REST OF LATIN AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 281
TABLE 328 REST OF LATIN AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY RESEARCH & DEVELOPMENT APPLICATION TYPE, 2023–2030 (USD MILLION) 281
TABLE 329 REST OF LATIN AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY CLINICAL TRIAL TYPE, 2023–2030 (USD MILLION) 281
TABLE 330 REST OF LATIN AMERICA: LIFE SCIENCE ANALYTICS MARKET FOR CLINICAL TRIALS, BY PHASE, 2023–2030 (USD MILLION) 282
TABLE 331 REST OF LATIN AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY COMMERCIAL ANALYTICS APPLICATION TYPE, 2023–2030 (USD MILLION) 282
TABLE 332 REST OF LATIN AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY SAFETY APPLICATION TYPE, 2023–2030 (USD MILLION) 282
TABLE 333 REST OF LATIN AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 283
TABLE 334 MIDDLE EAST & AFRICA: LIFE SCIENCE ANALYTICS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 284
TABLE 335 MIDDLE EAST & AFRICA: LIFE SCIENCE ANALYTICS MARKET, BY TYPE,
2023–2030 (USD MILLION) 284
TABLE 336 MIDDLE EAST & AFRICA: LIFE SCIENCE ANALYTICS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 285
TABLE 337 MIDDLE EAST & AFRICA: LIFE SCIENCE ANALYTICS MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 285
TABLE 338 MIDDLE EAST & AFRICA: LIFE SCIENCE ANALYTICS MARKET, BY MANAGED SERVICE TYPE, 2023–2030 (USD MILLION) 285
TABLE 339 MIDDLE EAST & AFRICA: LIFE SCIENCE ANALYTICS MARKET, BY PROFESSIONAL SERVICE TYPE, 2023–2030 (USD MILLION) 286
TABLE 340 MIDDLE EAST & AFRICA: LIFE SCIENCE ANALYTICS MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION) 286
TABLE 341 MIDDLE EAST & AFRICA: LIFE SCIENCE ANALYTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 286
TABLE 342 MIDDLE EAST & AFRICA: LIFE SCIENCE ANALYTICS MARKET, BY RESEARCH & DEVELOPMENT APPLICATION TYPE, 2023–2030 (USD MILLION) 287
TABLE 343 MIDDLE EAST & AFRICA: LIFE SCIENCE ANALYTICS MARKET, BY CLINICAL TRIAL TYPE, 2023–2030 (USD MILLION) 287
TABLE 344 MIDDLE EAST & AFRICA: LIFE SCIENCE ANALYTICS MARKET FOR CLINICAL TRIALS, BY PHASE, 2023–2030 (USD MILLION) 287
TABLE 345 MIDDLE EAST & AFRICA: LIFE SCIENCE ANALYTICS MARKET, BY COMMERCIAL ANALYTICS APPLICATION TYPE, 2023–2030 (USD MILLION) 288
TABLE 346 MIDDLE EAST & AFRICA: LIFE SCIENCE ANALYTICS MARKET, BY SAFETY APPLICATION TYPE, 2023–2030 (USD MILLION) 288
TABLE 347 MIDDLE EAST & AFRICA: LIFE SCIENCE ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 288
TABLE 348 GCC COUNTRIES: LIFE SCIENCE ANALYTICS MARKET, BY TYPE,
2023–2030 (USD MILLION) 289
TABLE 349 GCC COUNTRIES: LIFE SCIENCE ANALYTICS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 290
TABLE 350 GCC COUNTRIES: LIFE SCIENCE ANALYTICS MARKET, BY SERVICE TYPE,
2023–2030 (USD MILLION) 290
TABLE 351 GCC COUNTRIES: LIFE SCIENCE ANALYTICS MARKET, BY MANAGED SERVICE TYPE, 2023–2030 (USD MILLION) 290
TABLE 352 GCC COUNTRIES: LIFE SCIENCE ANALYTICS MARKET, BY PROFESSIONAL SERVICE TYPE, 2023–2030 (USD MILLION) 291
TABLE 353 GCC COUNTRIES: LIFE SCIENCE ANALYTICS MARKET, BY SOFTWARE TYPE,
2023–2030 (USD MILLION) 291
TABLE 354 GCC COUNTRIES: LIFE SCIENCE ANALYTICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 291
TABLE 355 GCC COUNTRIES: LIFE SCIENCE ANALYTICS MARKET, BY RESEARCH & DEVELOPMENT APPLICATION TYPE, 2023–2030 (USD MILLION) 292
TABLE 356 GCC COUNTRIES: LIFE SCIENCE ANALYTICS MARKET, BY CLINICAL TRIAL TYPE, 2023–2030 (USD MILLION) 292
TABLE 357 GCC COUNTRIES: LIFE SCIENCE ANALYTICS MARKET FOR CLINICAL TRIALS, BY PHASE, 2023–2030 (USD MILLION) 292
TABLE 358 GCC COUNTRIES: LIFE SCIENCE ANALYTICS MARKET, BY COMMERCIAL ANALYTICS APPLICATION TYPE, 2023–2030 (USD MILLION) 293
TABLE 359 GCC COUNTRIES: LIFE SCIENCE ANALYTICS MARKET, BY SAFETY APPLICATION TYPE, 2023–2030 (USD MILLION) 293
TABLE 360 GCC COUNTRIES: LIFE SCIENCE ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 293
TABLE 361 REST OF MIDDLE EAST & AFRICA: LIFE SCIENCE ANALYTICS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 294
TABLE 362 REST OF MIDDLE EAST & AFRICA: LIFE SCIENCE ANALYTICS MARKET,
BY COMPONENT, 2023–2030 (USD MILLION) 294
TABLE 363 REST OF MIDDLE EAST & AFRICA: LIFE SCIENCE ANALYTICS MARKET,
BY SERVICE TYPE, 2023–2030 (USD MILLION) 295
TABLE 364 REST OF MIDDLE EAST & AFRICA: LIFE SCIENCE ANALYTICS MARKET,
BY MANAGED SERVICE TYPE, 2023–2030 (USD MILLION) 295
TABLE 365 REST OF MIDDLE EAST & AFRICA: LIFE SCIENCE ANALYTICS MARKET,
BY PROFESSIONAL SERVICE TYPE, 2023–2030 (USD MILLION) 295
TABLE 366 REST OF MIDDLE EAST & AFRICA: LIFE SCIENCE ANALYTICS MARKET,
BY SOFTWARE TYPE, 2023–2030 (USD MILLION) 296
TABLE 367 REST OF MIDDLE EAST & AFRICA: LIFE SCIENCE ANALYTICS MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 296
TABLE 368 REST OF MIDDLE EAST & AFRICA: LIFE SCIENCE ANALYTICS MARKET, BY RESEARCH & DEVELOPMENT APPLICATION TYPE, 2023–2030 (USD MILLION) 296
TABLE 369 REST OF MIDDLE EAST & AFRICA: LIFE SCIENCE ANALYTICS MARKET, BY CLINICAL TRIAL TYPE, 2023–2030 (USD MILLION) 297
TABLE 370 REST OF MIDDLE EAST & AFRICA: LIFE SCIENCE ANALYTICS MARKET FOR CLINICAL TRIALS, BY PHASE, 2023–2030 (USD MILLION) 297
TABLE 371 REST OF MIDDLE EAST & AFRICA: LIFE SCIENCE ANALYTICS MARKET, BY COMMERCIAL ANALYTICS APPLICATION TYPE, 2023–2030 (USD MILLION) 297
TABLE 372 REST OF MIDDLE EAST & AFRICA: LIFE SCIENCE ANALYTICS MARKET, BY SAFETY APPLICATION TYPE, 2023–2030 (USD MILLION) 298
TABLE 373 REST OF MIDDLE EAST & AFRICA: LIFE SCIENCE ANALYTICS MARKET,
BY END USER, 2023–2030 (USD MILLION) 298
TABLE 374 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN LIFE SCIENCE ANALYTICS MARKET 300
TABLE 375 LIFE SCIENCE ANALYTICS MARKET: DEGREE OF COMPETITION 304
TABLE 376 LIFE SCIENCE ANALYTICS MARKET: REGION FOOTPRINT (25 COMPANIES) 308
TABLE 377 LIFE SCIENCE ANALYTICS MARKET: TYPE FOOTPRINT (25 COMPANIES) 309
TABLE 378 LIFE SCIENCE ANALYTICS MARKET: APPLICATION FOOTPRINT (25 COMPANIES) 310
TABLE 379 LIFE SCIENCE ANALYTICS MARKET: COMPONENT FOOTPRINT (25 COMPANIES) 311
TABLE 380 LIFE SCIENCE ANALYTICS MARKET: END USER FOOTPRINT (25 COMPANIES) 312
TABLE 381 LIFE SCIENCE ANALYTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 315
TABLE 382 LIFE SCIENCE ANALYTICS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS (STARTUPS/SMES) 316
TABLE 383 LIFE SCIENCE ANALYTICS MARKET: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2022–MARCH 2025 319
TABLE 384 LIFE SCIENCE ANALYTICS MARKET: DEALS, JANUARY 2022–MARCH 2025 320
TABLE 385 ORACLE: COMPANY OVERVIEW 323
TABLE 386 ORACLE: PRODUCTS & SERVICES OFFERED 324
TABLE 387 ORACLE: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2022–MARCH 2025 326
TABLE 388 ORACLE: DEALS, JANUARY 2022–MARCH 2025 326
TABLE 389 MERATIVE: COMPANY OVERVIEW 329
TABLE 390 MERATIVE: PRODUCTS & SERVICES OFFERED 329
TABLE 391 MERATIVE: DEALS, JANUARY 2022–MARCH 2025 330
TABLE 392 MERATIVE: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025 330
TABLE 393 SAS INSTITUTE: COMPANY OVERVIEW 332
TABLE 394 SAS INSTITUTE: PRODUCTS & SERVICES OFFERED 333
TABLE 395 SAS INSTITUTE: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2022–MARCH 2025 333
TABLE 396 SAS INSTITUTE: DEALS, JANUARY 2022–MARCH 2025 334
TABLE 397 ACCENTURE: COMPANY OVERVIEW 336
TABLE 398 ACCENTURE: PRODUCTS OFFERED 338
TABLE 399 ACCENTURE: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2022–MARCH 2025 338
TABLE 400 ACCENTURE: DEALS, JANUARY 2022–MARCH 2025 339
TABLE 401 ACCENTURE: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025 339
TABLE 402 IQVIA: COMPANY OVERVIEW 341
TABLE 403 IQVIA: PRODUCTS & SERVICES OFFERED 342
TABLE 404 IQVIA: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2022–MARCH 2025 344
TABLE 405 IQVIA: DEALS, JANUARY 2022–MARCH 2025 345
TABLE 406 IQVIA: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025 345
TABLE 407 COGNIZANT: COMPANY OVERVIEW 347
TABLE 408 COGNIZANT: PRODUCTS & SERVICES OFFERED 348
TABLE 409 COGNIZANT: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2022–MARCH 2025 350
TABLE 410 COGNIZANT: DEALS, JANUARY 2022–MARCH 2025 350
TABLE 411 WIPRO: COMPANY OVERVIEW 351
TABLE 412 WIPRO: PRODUCTS & SERVICES OFFERED 353
TABLE 413 WIPRO: DEALS, JANUARY 2022–MARCH 2025 354
TABLE 414 VERADIGM: COMPANY OVERVIEW 355
TABLE 415 VERADIGM: PRODUCTS & SERVICES OFFERED 356
TABLE 416 VERADIGM: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2022–MARCH 2025 357
TABLE 417 VERADIGM: DEALS, JANUARY 2022–MARCH 2025 357
TABLE 418 OPTUM: COMPANY OVERVIEW 358
TABLE 419 OPTUM: PRODUCTS & SERVICES OFFERED 359
TABLE 420 MICROSOFT: COMPANY OVERVIEW 360
TABLE 421 MICROSOFT: PRODUCTS & SERVICES OFFERED 361
TABLE 422 MICROSOFT: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2022–MARCH 2025 362
TABLE 423 MICROSOFT: DEALS, JANUARY 2022–MARCH 2025 362
TABLE 424 MAXISIT: COMPANY OVERVIEW 363
TABLE 425 MAXISIT: PRODUCTS & SERVICES OFFERED 363
TABLE 426 MAXISIT: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2022–MARCH 2025 364
TABLE 427 EXLSERVICE HOLDINGS: COMPANY OVERVIEW 365
TABLE 428 EXLSERVICE HOLDINGS: PRODUCTS & SERVICES OFFERED 366
TABLE 429 EXLSERVICE HOLDINGS: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2022–MARCH 2025 367
TABLE 430 EXLSERVICE HOLDINGS: DEALS, JANUARY 2022–MARCH 2025 367
TABLE 431 INOVALON: COMPANY OVERVIEW 368
TABLE 432 INOVALON: PRODUCTS & SERVICES OFFERED 369
TABLE 433 INOVALON: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2022–MARCH 2025 370
TABLE 434 INOVALON: DEALS, JANUARY 2022–MARCH 2025 370
TABLE 435 CITIUSTECH: COMPANY OVERVIEW 371
TABLE 436 CITIUSTECH: PRODUCTS & SERVICES OFFERED 371
TABLE 437 CITIUSTECH: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2022–MARCH 2025 372
TABLE 438 CITIUSTECH: DEALS, JANUARY 2022–MARCH 2025 373
TABLE 439 CITIUSTECH: EXPANSIONS, JANUARY 2022–MARCH 2025 373
TABLE 440 SAAMA: COMPANY OVERVIEW 374
TABLE 441 SAAMA: PRODUCTS & SERVICES OFFERED 374
TABLE 442 SAAMA: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2022–MARCH 2025 375
TABLE 443 SAAMA: DEALS, JANUARY 2022–MARCH 2025 376
TABLE 444 SAAMA: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025 376
TABLE 445 AXTRIA: COMPANY OVERVIEW 377
TABLE 446 AXTRIA: PRODUCTS & SERVICES OFFERED 377
TABLE 447 AXTRIA: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2022–MARCH 2025 378
TABLE 448 AXTRIA: DEALS, JANUARY 2022–MARCH 2025 378
TABLE 449 AXTRIA: EXPANSIONS, JANUARY 2022–MARCH 2025 378
TABLE 450 CLARIVATE: COMPANY OVERVIEW 379
TABLE 451 CLARIVATE: PRODUCTS & SERVICES OFFERED 381
TABLE 452 CLARIVATE: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2022–MARCH 2025 382
TABLE 453 CLARIVATE: DEALS, JANUARY 2022–MARCH 2025 383
TABLE 454 THOUGHTSPHERE: COMPANY OVERVIEW 384
TABLE 455 THOUGHTSPHERE: PRODUCTS & SERVICES OFFERED 385
TABLE 456 THOUGHTSPOT: COMPANY OVERVIEW 386
TABLE 457 THOUGHTSPOT: PRODUCTS & SERVICES OFFERED 386
TABLE 458 THOUGHTSPOT: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2022–MARCH 2025 387
TABLE 459 THOUGHTSPOT: DEALS, JANUARY 2022–MARCH 2025 387
TABLE 460 SALESFORCE: COMPANY OVERVIEW 388
TABLE 461 SALESFORCE: PRODUCTS & SERVICES OFFERED 389
TABLE 462 SALESFORCE: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2022–MARCH 2025 390
TABLE 463 SALESFORCE: DEALS, JANUARY 2022–MARCH 2025 390
LIST OF FIGURES
FIGURE 1 RESEARCH DESIGN 42
FIGURE 2 PRIMARY SOURCES 44
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 45
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 46
FIGURE 5 LIFE SCIENCE ANALYTICS MARKET: REVENUE SHARE ANALYSIS ILLUSTRATION 47
FIGURE 6 BOTTOM-UP APPROACH: END-USER SPENDING ON LIFE SCIENCE ANALYTICS 48
FIGURE 7 LIFE SCIENCE ANALYTICS MARKET: CAGR PROJECTION FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2025–2030) 49
FIGURE 8 CAGR PROJECTION: SUPPLY-SIDE ANALYSIS 50
FIGURE 9 TOP-DOWN APPROACH 50
FIGURE 10 DATA TRIANGULATION METHODOLOGY 51
FIGURE 11 LIFE SCIENCE ANALYTICS MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION) 54
FIGURE 12 LIFE SCIENCE ANALYTICS MARKET, BY COMPONENT,
2025 VS. 2030 (USD MILLION) 55
FIGURE 13 LIFE SCIENCE ANALYTICS MARKET, BY APPLICATION,
2025 VS. 2030 (USD MILLION) 55
FIGURE 14 LIFE SCIENCE ANALYTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 56
FIGURE 15 LIFE SCIENCE ANALYTICS MARKET: REGIONAL SNAPSHOT 57
FIGURE 16 RISING TECHNOLOGICAL ADVANCEMENTS AND GROWING ADOPTION OF ANALYTICS SOLUTIONS FOR CLINICAL TRIALS TO DRIVE MARKET 58
FIGURE 17 NORTH AMERICA TO DOMINATE LIFE SCIENCE ANALYTICS
MARKET THROUGHOUT FORECAST PERIOD 59
FIGURE 18 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND US HELD LARGEST MARKET SHARE IN NORTH AMERICA IN 2024 60
FIGURE 19 CHINA TO REGISTER HIGHEST CAGR IN GLOBAL MARKET
DURING FORECAST PERIOD 61
FIGURE 20 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 61
FIGURE 21 LIFE SCIENCE ANALYTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 62
FIGURE 22 HEALTH EXPENDITURE AS SHARE OF GDP, 2022 (OR NEAREST YEAR) 64
FIGURE 23 LIFE SCIENCE ANALYTICS MARKET ECOSYSTEM 80
FIGURE 24 LIFE SCIENCE ANALYTICS MARKET: VALUE CHAIN ANALYSIS 82
FIGURE 25 LIFE SCIENCE ANALYTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 83
FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS 86
FIGURE 27 KEY BUYING CRITERIA FOR END USERS 87
FIGURE 28 REVENUE SHIFT IN LIFE SCIENCE ANALYTICS MARKET 98
FIGURE 29 JURISDICTION ANALYSIS: TOP APPLICANTS FOR LIFE SCIENCE ANALYTICS PATENTS, JANUARY 2011–MARCH 2025 99
FIGURE 30 MAJOR PATENTS FOR LIFE SCIENCE ANALYTICS, JANUARY 2011– MARCH 2025 100
FIGURE 31 FUNDING OF PLAYERS IN LIFE SCIENCE ANALYTICS MARKET 106
FIGURE 32 MARKET POTENTIAL OF AI/GENERATIVE AI, BY INDUSTRY 109
FIGURE 33 IMPACT OF GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 112
FIGURE 34 NORTH AMERICA: LIFE SCIENCE ANALYTICS MARKET SNAPSHOT 187
FIGURE 35 ASIA PACIFIC: LIFE SCIENCE ANALYTICS MARKET SNAPSHOT 238
FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS IN LIFE SCIENCE ANALYTICS MARKET, 2020–2024 303
FIGURE 37 LIFE SCIENCE ANALYTICS MARKET: MARKET SHARE ANALYSIS (2024) 304
FIGURE 38 LIFE SCIENCE ANALYTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 306
FIGURE 39 LIFE SCIENCE ANALYTICS MARKET: COMPANY FOOTPRINT (25 COMPANIES) 307
FIGURE 40 LIFE SCIENCE ANALYTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 314
FIGURE 41 EV/EBITDA OF KEY VENDORS 318
FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF LIFE SCIENCE ANALYTICS VENDORS 318
FIGURE 43 ORACLE: COMPANY SNAPSHOT 324
FIGURE 44 ACCENTURE: COMPANY SNAPSHOT 337
FIGURE 45 IQVIA: COMPANY SNAPSHOT 342
FIGURE 46 COGNIZANT: COMPANY SNAPSHOT 348
FIGURE 47 WIPRO: COMPANY SNAPSHOT 352
FIGURE 48 VERADIGM: COMPANY SNAPSHOT 356
FIGURE 49 UNITED HEALTH GROUP: COMPANY SNAPSHOT 358
FIGURE 50 MICROSOFT: COMPANY SNAPSHOT 361
FIGURE 51 EXLSERVICE HOLDINGS: COMPANY SNAPSHOT 366
FIGURE 52 CLARIVATE: COMPANY SNAPSHOT 380
FIGURE 53 SALESFORCE: COMPANY SNAPSHOT 389
MarketsandMarkets（マーケッツアンドマーケッツ）は広範な市場を対象にした市場調査レポートを出版しています。世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | USD9,150 | USD9,650 | USD11,500 |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- UV安定剤市場 – 2030年までの世界予測 2025-05-16
- 産業用通信市場 – 2030年までの世界予測 2025-05-16
- 経腸栄養装置市場 – 2030年までの世界予測 2025-05-15
- データセンターGPU市場 – 2030年までの世界予測 2025-05-15
- ステンレス鋼シームレスパイプ市場 – 2030年までの世界予測 2025-05-15